A U.S. appeals court has reinstated more than 500 lawsuits against drugmaker Merck & Co. because of its osteoporosis drug Fosamax, which plaintiffs allege increases risk of thigh bone fractures, according to court documents reviewed by Becker’s.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
